Definition: (G144132)

Target Name: DNHD1

NCBI ID: G144132

DNHD1

Definition:

DNHD1 (Dihydroorotate Hydrotransferase 1) is a protein that plays a critical role in the regulation of DNA damage repair in eukaryotic cells. It is a member of the DNA damage repair machinery and is involved in the repair of various types of DNA damage, including double-strand breaks and single-strand breaks. DNHD1 is also involved in the processing of DNA repair intermediates and in the regulation of the DNA double-strand break repair pathway.

Background:

DNA damage repair is a critical component of cellular homeostasis and is involved in the maintenance of the integrity of the genetic material. DNA damage can arise from various sources, including mutations, deletions, and insertions. These events can lead to the formation of DNA repair intermediates that need to be processed and repaired by the DNA damage repair machinery.

DNHD1 is a key enzyme involved in the processing of DNA repair intermediates and in the regulation of the DNA double-strand break repair pathway. It is composed of a catalytic core and two transmembrane regions. The catalytic core contains the active site for the hydrotransferase reaction, which is the critical step in the repair process. The transmembrane regions contain the substrate recognition sites and the regulatory interactions with other proteins.

DNHD1 functions as a DNA damage repair enzyme by processing DNA repair intermediates and regulating the DNA double-strand break repair pathway. It is involved in the repair of various types of DNA damage, including double-strand breaks, single-strand breaks, and insertions.

DNHD1 is also involved in the regulation of the DNA double-strand break repair pathway. It plays a critical role in the processing of DNA repair intermediates that are required for the initiation of the repair process. It is also involved in the regulation of the DNA damage repair machinery, including the composition of the repair complex and the contribution of various proteins to the repair process.

DNHD1 is a drug target (or biomarker) because it is a key enzyme involved in the regulation of DNA damage repair and its dysregulation has been implicated in various diseases, including cancer.

DNHD1 is a protein that is expressed in a variety of tissues and cells, including the nucleus, the cytoplasm, and the mitochondria. It is also expressed in various cellular processes, including DNA replication, transcription, and gene expression.

DNHD1 is a protein that is involved in the regulation of cellular processes that are critical for the maintenance of cellular homeostasis. It is a potential drug target (or biomarker) due to its involvement in the regulation of DNA damage repair and its dysregulation in various diseases.

Conclusion:

In conclusion, DNHD1 (Dihydroorotate Hydrotransferase 1) is a protein that is involved in the regulation of DNA damage repair in eukaryotic cells. It is a key enzyme in the DNA damage repair machinery and is involved in the repair of various types of DNA damage, including double-strand breaks and single-strand breaks. DNHD1 is also involved in the regulation of the DNA double-strand break repair pathway and its dysregulation has been implicated in various diseases, including cancer. Therefore, DNHD1 is a potential drug target (or biomarker) and further research is needed to understand its role in the regulation of DNA damage repair and its potential as a therapeutic target.

Protein Name: Dynein Heavy Chain Domain 1

Functions: Essential for the normal assembly and function of sperm flagella axonemes

The "DNHD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNHD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets